- RAG rating
- n/a
- Document type
- Clinical pathways
- Place
- Hertfordshire and West Essex ICB
- Output type
- Clinical Pathways
- Pathway
- PSA Pathway
PSA Pathway
Pathway published: June 2024
Next review date: June 2026
Patient request a PSA test
Consider appropriateness of the test, including:
• Life expectancy
• Age
• Family history of prostate cancer
• Risk factors for prostate cancer, including: black ethnic origin, family history of prostate cancer, increasing age, germline mutations (HOXB13, BRCA1/2).
• Previous diagnosis of prostate cancer
Consider appropriateness of the test, including:
• Life expectancy
• Age
• Family history of prostate cancer
• Risk factors for prostate cancer, including: black ethnic origin, family history of prostate cancer, increasing age, germline mutations (HOXB13, BRCA1/2).
• Previous diagnosis of prostate cancer
Note PSA results should be doubled for
interpretation if patient on 5-alpha
reductase inhibitor (finasteride /
dutasteride)
For asymptomatic men with a life expectancy of less than 10 years, PSA testing is not recommended as it is unlikely to benefit them, unless requested by a urologist
For asymptomatic men with a life expectancy of less than 10 years, PSA testing is not recommended as it is unlikely to benefit them, unless requested by a urologist
Please see pathway attached for further information.